Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 434

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors

Open access
Suresh, Karthik, Voong, Khinh Ranh, Shankar, Bairavi, Forde, Patrick M., Ettinger, David S., Marrone, Kristen A., Kelly, Ronan J., Hann, Christine L., Levy, Benjamin, Feliciano, Josephine L., Brahmer, Julie R., Feller-Kopman, David, Lerner, Andrew D., Lee, Hans, Yarmus, Lonny, D’Alessio, Franco, Hales, Russell K., Lin, Cheng Ting, Psoter, Kevin J., Danoff, Sonye K., Naidoo, Jarushka · 2018 · Journal of Thoracic Oncology

Abstract

Checkpoint inhibitor pneumonitis (CIP) is an immune‐related adverse event that can occur after initiation of anti–programmed death 1/programmed death ligand 1 immune checkpoint inhibitor (ICI) therapy for the treatment of multiple malignancies, including NSCLC. However, the incidence of CIP has not been previously examined in a population that included both trial‐enrolled and non–trial‐enrolled patients with advanced NSCLC. Furthermore, risk factors and other clinical characteristics associated with CIP severity are not known. In this study, we retrospectively examined clinical characteristics, incidence, and risk factors for CIP in a cohort of 205 patients with NSCLC, all of whom received anti–programmed death 1/programmed death ligand 1 ICIs. Our results demonstrate a higher incidence of CIP (19%) than previously reported in clinical trials (3%–5%). Our data also suggest that tumor histologic type may be a risk factor for CIP development. We observed a wide range of time to onset of CIP (median 82 days), with high morbidity and mortality associated with higher‐grade CIP regardless of degree of immunosuppression. Our data provide new insight into the epidemiology and clinical characteristics of CIP. Further studies are needed to increase CIP pharmacovigilance, improve risk stratification, and refine diagnostic algorithms for the diagnosis and management of this potential life‐threatening complication of ICI therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2018.08.2035

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 434

Metadata

Authors
Suresh, K., Voong, K. R., Shankar, B., Forde, P. M., Ettinger, D. S., Marrone, K. A., Kelly, R. J., Hann, C. L., Levy, B., Feliciano, J. L., Brahmer, J. R., Feller-Kopman, D., Lerner, A. D., Lee, H., Yarmus, L., D’Alessio, F., Hales, R. K., Lin, C. T., Psoter, K. J., Danoff, S. K., & Naidoo, J.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2018-12
Volume
13
Issue
12
Pages
1930-1939
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2893321040
Cited by
434
References
20
FWCI
13.31
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. https://app.cochat.ai/papers/10.1016/j.jtho.2018.08.2035
The paper
Suresh, K., Voong, K. R., Shankar, B., Forde, P. M., Ettinger, D. S., Marrone, K. A., Kelly, R. J., Hann, C. L., Levy, B., Feliciano, J. L., Brahmer, J. R., Feller-Kopman, D., Lerner, A. D., Lee, H., Yarmus, L., D’Alessio, F., Hales, R. K., Lin, C. T., Psoter, K. J., . . . Naidoo, J. (2018). Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2018.08.2035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.